Gossamer Bio/$GOSS

13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX

About Gossamer Bio

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Ticker

$GOSS
Sector
Primary listing

Employees

145

Gossamer Bio Metrics

BasicAdvanced
$589M
-
-$0.61
1.96
-

What the Analysts think about Gossamer Bio

Analyst ratings (Buy, Hold, Sell) for Gossamer Bio stock.

Bulls say / Bears say

Gossamer Bio has completed enrollment for the pivotal Phase 3 PROSERA Study, enrolling over 350 PAH patients. This milestone helps de-risk the program and paves the way for a pivotal top-line data readout anticipated in February 2026. (Business Wire)
As of June 30, 2025, Gossamer Bio reported $212.9 million in cash, cash equivalents, and marketable securities, providing it with funding through 2027 to support its late-stage development plans. (Business Wire)
Seralutinib was granted Orphan Drug Designation for PAH in Japan on January 31, 2025. This designation may accelerate regulatory approvals and increase market exclusivity in an important region. (BioSpace)
Data summarised monthly by Lightyear AI. Last updated on 29 Aug 2025.

Gossamer Bio Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Gossamer Bio Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $GOSS

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs